NM Physician's Notes · ¹⁷⁷Lu-DOTATATE

NETTER-2 moves PRRT to first-line for grade 2/3 GEP-NETs.

Until 2024 ¹⁷⁷Lu-DOTATATE PRRT was a second-line option, reserved for patients progressing after somatostatin-analogue therapy. NETTER-2 changed that. In a randomised first-line setting, ¹⁷⁷Lu-DOTATATE plus octreotide tripled median PFS (22.8 vs 8.5 months) and quadrupled ORR (43 % vs 9.3 %). This post unpacks what that means for the Indian centre's PRRT selection SOP.

NETTER-2 — headline numbers

First-line ¹⁷⁷Lu-DOTATATE vs high-dose octreotide

Endpoint	¹⁷⁷Lu-DOTATATE + octreotide	High-dose octreotide	Effect
Median PFS	22.8 months	8.5 months	HR 0.276
Objective Response Rate	43.0 %	9.3 %	≈4.6× higher
Disease control rate	90.5 %	64.8 %	+25.7 pp
Grade ≥3 adverse events	34 %	24 %	+10 pp

Source: Singh S et al. NETTER-2: ¹⁷⁷Lu-DOTATATE plus long-acting octreotide vs high-dose long-acting octreotide for the treatment of newly diagnosed advanced grade 2-3 GEP-NETs. Lancet 2024; 403:2807–2817.

The clinical positioning shift

From second-line salvage to first-line offering

Before NETTER-2 (≤2023)

PRRT positioned as second-line after somatostatin-analogue failure (octreotide LAR or lanreotide)
Average patient delay from diagnosis to PRRT: 18–24 months while waiting on SSA progression
Grade 3 NETs not on label — restricted to clinical-trial pathways
Indian centres restricted PRRT to NETTER-1 phenotype (midgut SSTR2+ progressors)

After NETTER-2 (2024+)

PRRT moves to first-line for advanced grade 2 / well-differentiated grade 3 GEP-NETs
Patient selected at diagnosis MDT — no octreotide-failure prerequisite
Grade 3 well-differentiated NETs included on label (Ki-67 up to 55 %)
Indian centres re-write the PRRT eligibility SOP for first-line presentation

Patient-selection checklist — first-line

The six criteria the MDT confirms before referral

Histologic confirmation of well-differentiated GEP-NET, grade 1 / 2 / well-differentiated grade 3 (Ki-67 up to ~55 % on NETTER-2)
Ga-68 DOTATATE PET/CT showing SSTR2 expression at Krenning score 3–4 in target lesions (uptake ≥ liver / ≥ spleen)
Adequate renal function — eGFR ≥ 50 mL/min, no obstructive uropathy without intervention
Adequate bone-marrow function — Hb ≥ 8 g/dL, WBC ≥ 2.0 × 10⁹/L, platelets ≥ 75 × 10⁹/L
ECOG performance status 0–2
No competing alternative on which response is expected within 6 months (e.g. surgical resection candidate)

Lu-177 + DOTATATE

More for this product

Sibling posts in the ¹⁷⁷Lu-DOTATATE family.

For Nuclear-Medicine Physician

Nuclear-Medicine Physician

Why Lu-177 purity changes PRRT

Across four cycles, three Lu-177 specs decide SSTR2 receptor saturation, kidney dose tail and labelling yield. Why ≥ 3,000 GBq/mg specific activity, ≥ 99.9 % RNP and ≥ 99 % RCP are what NETTER chemistry actually requires.

Read this